TY - JOUR
T1 - Emerging therapeutic targets for idiopathic pulmonary fibrosis
T2 - preclinical progress and therapeutic implications
AU - Yanagihara, Toyoshi
AU - Scallan, Ciaran
AU - Ask, Kjetil
AU - Kolb, Martin R.J.
N1 - Funding Information:
T. Yanagihara was funded by the Uehara Memorial Foundation Research Fellowship and Mitacs Canada. C. Scallan receives grants from the Canadian Pulmonary Fibrosis Foundation and personal fees from Boehringer Ingelheim. K. Ask reports grants and personal fees from Boehringer Ingelheim, grants from Canadian Pulmonary Fibrosis Foundation, Synairgen, Alkermes, GlaxoSmitheKline, Pharmaxis, Unity, Avalyn, Canadian Institutes of Health Research, Ceapro, Pieris, outside the submitted work. M. Kolb reports grants from the Canadian Institute for Health Research and grants/personal fees from Roche, Boehringer Ingelheim, Prometic, Respivert, Alkermes, and Pharmaxis and personal fees from Genoa. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high associated morbidity and mortality. The therapeutic landscape has significantly changed in the last 20 years with two drugs currently approved that have demonstrated the ability to slow disease progression. Despite these developments, survival in IPF is limited, so there is a major interest in therapeutic targets which could serve to open up new therapeutic avenues. Areas covered: We review the most recent information regarding drug targets and therapies currently being investigated in preclinical and early-stage clinical trials. Expert opinion: The complex pathogenesis of IPF and variability in disease course and response to therapy highlights the importance of a precision approach to therapy. Novel technologies including transcriptomics and the use of serum biomarkers, will become essential tools to guide future drug development and therapeutic decision making particularly as it pertains to combination therapy.
AB - Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high associated morbidity and mortality. The therapeutic landscape has significantly changed in the last 20 years with two drugs currently approved that have demonstrated the ability to slow disease progression. Despite these developments, survival in IPF is limited, so there is a major interest in therapeutic targets which could serve to open up new therapeutic avenues. Areas covered: We review the most recent information regarding drug targets and therapies currently being investigated in preclinical and early-stage clinical trials. Expert opinion: The complex pathogenesis of IPF and variability in disease course and response to therapy highlights the importance of a precision approach to therapy. Novel technologies including transcriptomics and the use of serum biomarkers, will become essential tools to guide future drug development and therapeutic decision making particularly as it pertains to combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=85121690413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121690413&partnerID=8YFLogxK
U2 - 10.1080/14728222.2021.2006186
DO - 10.1080/14728222.2021.2006186
M3 - Review article
C2 - 34784834
AN - SCOPUS:85121690413
SN - 1472-8222
VL - 25
SP - 939
EP - 948
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 11
ER -